JP2015500836A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015500836A5 JP2015500836A5 JP2014546156A JP2014546156A JP2015500836A5 JP 2015500836 A5 JP2015500836 A5 JP 2015500836A5 JP 2014546156 A JP2014546156 A JP 2014546156A JP 2014546156 A JP2014546156 A JP 2014546156A JP 2015500836 A5 JP2015500836 A5 JP 2015500836A5
- Authority
- JP
- Japan
- Prior art keywords
- opn
- seq
- variant
- opn variant
- active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 19
- 201000011510 cancer Diseases 0.000 claims 12
- 239000012634 fragment Substances 0.000 claims 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 206010027476 Metastases Diseases 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161567899P | 2011-12-07 | 2011-12-07 | |
| US61/567,899 | 2011-12-07 | ||
| US201261673912P | 2012-07-20 | 2012-07-20 | |
| US61/673,912 | 2012-07-20 | ||
| EP12177329 | 2012-07-20 | ||
| EP12177329.5 | 2012-07-20 | ||
| PCT/US2012/068628 WO2013086459A1 (en) | 2011-12-07 | 2012-12-07 | Osteopontin variants for use in suppression or prevention of tumor growth and compositions containing such osteopontin variants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015500836A JP2015500836A (ja) | 2015-01-08 |
| JP2015500836A5 true JP2015500836A5 (OSRAM) | 2016-02-12 |
Family
ID=48574961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546156A Pending JP2015500836A (ja) | 2011-12-07 | 2012-12-07 | 腫瘍増殖の抑制または防止に使用されるオステオポンチン変異体、およびそうしたオステオポンチン変異体を含む組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150344534A1 (OSRAM) |
| EP (1) | EP2788015A1 (OSRAM) |
| JP (1) | JP2015500836A (OSRAM) |
| KR (1) | KR20140104474A (OSRAM) |
| CN (1) | CN104080472A (OSRAM) |
| AR (1) | AR089136A1 (OSRAM) |
| AU (1) | AU2012347468A1 (OSRAM) |
| BR (1) | BR112014013565A2 (OSRAM) |
| CA (1) | CA2858379A1 (OSRAM) |
| EA (1) | EA201491010A1 (OSRAM) |
| WO (1) | WO2013086459A1 (OSRAM) |
| ZA (1) | ZA201404920B (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ715430A (en) | 2013-07-05 | 2022-01-28 | Arla Foods Amba | Mammalian milk osteopontin for enhancing immune responsiveness |
| EP4326758A4 (en) * | 2021-04-20 | 2025-03-19 | University of Cincinnati | A vaccine adjuvant for infectious diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5888552A (en) * | 1988-04-29 | 1999-03-30 | Immunotec Research Corporation Ltd. | Anti-cancer therapeutic compositions containing whey protein concentrate |
| IL106576A (en) * | 1992-08-13 | 2000-08-13 | Immunotec Res Corp Ltd | Anti-cancer therapeutic compositions for prophylaxis or for treatment of cancer |
| EP1175223A2 (en) * | 1999-04-15 | 2002-01-30 | Children's Medical Center Corporation | Methods and compositions for modulating an immune response |
| US7259243B2 (en) * | 2000-01-07 | 2007-08-21 | Arla Foods Amba | Process for isolation of osteopontin from milk |
| NZ507335A (en) * | 2000-10-05 | 2004-10-29 | New Zealand Dairy Board | Bone health compositions derived from milk comprising an acidic protein fraction but that does not contain CGMP |
| EP1667537B1 (en) * | 2003-09-18 | 2013-11-06 | Arla Foods Amba | Infant formula |
| SM200600031B (it) * | 2006-10-06 | 2009-05-11 | Gianluca Mech | Integratore alimentare con attivatore proteico |
| ES2538362T3 (es) * | 2007-10-16 | 2015-06-19 | Ventana Medical Systems, Inc. | Clasificación, estadificación y pronóstico del cáncer mediante el uso de osteopontina-C |
-
2012
- 2012-12-07 US US14/363,565 patent/US20150344534A1/en not_active Abandoned
- 2012-12-07 EP EP12806797.2A patent/EP2788015A1/en not_active Withdrawn
- 2012-12-07 CA CA2858379A patent/CA2858379A1/en not_active Abandoned
- 2012-12-07 CN CN201280068303.6A patent/CN104080472A/zh active Pending
- 2012-12-07 BR BR112014013565A patent/BR112014013565A2/pt not_active IP Right Cessation
- 2012-12-07 WO PCT/US2012/068628 patent/WO2013086459A1/en not_active Ceased
- 2012-12-07 KR KR1020147018717A patent/KR20140104474A/ko not_active Withdrawn
- 2012-12-07 JP JP2014546156A patent/JP2015500836A/ja active Pending
- 2012-12-07 AU AU2012347468A patent/AU2012347468A1/en not_active Abandoned
- 2012-12-07 EA EA201491010A patent/EA201491010A1/ru unknown
- 2012-12-10 AR ARP120104631A patent/AR089136A1/es unknown
-
2014
- 2014-07-04 ZA ZA2014/04920A patent/ZA201404920B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534308A5 (OSRAM) | ||
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| JP2021505661A5 (OSRAM) | ||
| JP2014528914A5 (OSRAM) | ||
| EA201490911A1 (ru) | Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина | |
| JP2015517511A5 (OSRAM) | ||
| JP2018509388A5 (OSRAM) | ||
| CN1429114A (zh) | 联合化学疗法 | |
| JP2020537695A (ja) | ストレプトニグリンおよびラパマイシンを有効成分として含む、癌の予防または治療用薬学的組成物 | |
| Zhao et al. | A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer | |
| Elias et al. | L-arginine as an adjuvant drug in the treatment of sickle cell anaemia. | |
| Zhang et al. | The importance of N6-methyladenosine modification in tumor immunity and immunotherapy | |
| JP2016512247A5 (OSRAM) | ||
| JP2016505050A5 (OSRAM) | ||
| RU2015119377A (ru) | Лекарственные формы леводопы для быстрого купирования болезни паркинсона | |
| MX2013003523A (es) | Composicion farmaceutica de dosis baja. | |
| JP2015500836A5 (OSRAM) | ||
| WO2011031890A4 (en) | Cancer stem cell-targeted and drug resistant cancer therapy | |
| JP2017508737A5 (OSRAM) | ||
| JP2018530525A5 (OSRAM) | ||
| JP2009538935A5 (OSRAM) | ||
| CN109528731B (zh) | 具有协同作用治疗多发性骨髓瘤的药物组合物及其应用 | |
| US20150110864A1 (en) | Novel antitumor agent comprising combination of three agents | |
| MX2007004104A (es) | Uso de aceite de lavanda para la profilaxis y el tratamiento de neurastenia, problemas de somatizacion y otras enfermedades asociadas con la tension. |